Plasma proteomics for risk prediction of Alzheimer's disease in the general population
Aging Cell · 2024
DOI: 10.1111/acel.14330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2024. Verfasst von Sisi Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Proteomics. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, National Natural Science Foundation of China, Key Technologies R&D Program of Guangdong Province.
Themen: Demenz
Abstract (Originalsprache)
We aimed to develop and validate a protein risk score for predicting Alzheimer's disease (AD) and compare its performance with a validated clinical risk model (Cognitive Health and Dementia Risk Index for AD [CogDrisk‐AD]) and apolipoprotein E (APOE) genotypes. The development cohort, consisting of 35,547 participants from England in the UK Biobank, was randomly divided into a 7:3 training–testing ratio. The validation cohort included 4667 participants from Scotland and Wales in the UK Biobank. In the training set, an AD protein risk score was constructed using 31 proteins out of 2911 proteins. In the testing set, the AD protein risk score had a C‐index of 0.867 (95% CI, 0.828, 0.906) for AD prediction, followed by CogDrisk‐AD risk factors (C‐index, 0.856; 95% CI, 0.823, 0.889), and APOE genotypes (C‐index, 0.705; 95% CI, 0.660, 0.750). Adding the AD protein risk score to CogDrisk‐AD risk factors (C‐index increase, 0.050; 95% CI, 0.008, 0.093) significantly improved the predictive performance for AD. However, adding CogDrisk‐AD risk factors (C‐index increase, 0.040; 95% CI, −0.007, 0.086) or APOE genotypes (C‐index increase, 0.000; 95% CI, −0.054, 0.055) to the AD protein risk score did not significantly improve the predictive performance for AD. The top 10 proteins with the highest coefficients in the AD protein risk score contributed most of the predictive power for AD risk. These results were verified in the external validation cohort. EGFR, GFAP, and CHGA were identified as key proteins within the protein network. Our result suggests that the AD protein risk score demonstrated a good predictive performance for AD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- National Clinical Research Center for Kidney Disease, Guangzhou, China.
- State Key Laboratory of Organ Failure Research, Guangzhou, China.
- Guangdong Provincial Institute of Nephrology, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China.
ORCID-Profile: Xianhui Qin
Förderung
- National Key Research and Development Program
- National Natural Science Foundation of China
- Key Technologies R&D Program of Guangdong Province
- Guangdong Provincial Clinical Research Center for Kidney Disease
- the Program of Introducing Talents of Discipline to Universities, 111 Plan
- National Key Research and Development Program of China
Zitieren
APA
Yang, S., Ye, Z., He, P., Zhang, Y., Liu, M., Zhou, C., Zhang, Y., Gan, X., Huang, Y., Xiang, H., & Qin, X. (2024). Plasma proteomics for risk prediction of Alzheimer's disease in the general population. Aging Cell. https://doi.org/10.1111/acel.14330
Vancouver
Yang S, Ye Z, He P, Zhang Y, Liu M, Zhou C, et al. Plasma proteomics for risk prediction of Alzheimer's disease in the general population. Aging Cell. 2024. doi:10.1111/acel.14330
BibTeX
@article{Yang2024,
author = {Yang, Sisi and Ye, Ziliang and He, Panpan and Zhang, Yuanyuan and Liu, Mengyi and Zhou, Chun and Zhang, Yanjun and Gan, Xiaoqin and Huang, Yu and Xiang, Hao and Qin, Xianhui},
title = {Plasma proteomics for risk prediction of Alzheimer's disease in the general population},
journal = {Aging Cell},
year = {2024},
doi = {10.1111/acel.14330}
}
EUVIMED